DE69131796T2 - Analoge des ajca-ribosids - Google Patents

Analoge des ajca-ribosids

Info

Publication number
DE69131796T2
DE69131796T2 DE69131796T DE69131796T DE69131796T2 DE 69131796 T2 DE69131796 T2 DE 69131796T2 DE 69131796 T DE69131796 T DE 69131796T DE 69131796 T DE69131796 T DE 69131796T DE 69131796 T2 DE69131796 T2 DE 69131796T2
Authority
DE
Germany
Prior art keywords
analogs
riboside
ajca
ribofuranosylimidazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131796T
Other languages
English (en)
Other versions
DE69131796D1 (de
Inventor
David Bullough
Harry Gruber
Ernest Metzner
Kevin Mullane
Bheemarao Ugarkar
Clinton Browne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of DE69131796D1 publication Critical patent/DE69131796D1/de
Publication of DE69131796T2 publication Critical patent/DE69131796T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Amplifiers (AREA)
  • Electronic Switches (AREA)
  • Networks Using Active Elements (AREA)
  • Peptides Or Proteins (AREA)
DE69131796T 1990-08-10 1991-08-09 Analoge des ajca-ribosids Expired - Lifetime DE69131796T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56619690A 1990-08-10 1990-08-10
US73218291A 1991-07-17 1991-07-17
PCT/US1991/005696 WO1992002214A1 (en) 1990-08-10 1991-08-09 Aica riboside analogs

Publications (2)

Publication Number Publication Date
DE69131796D1 DE69131796D1 (de) 1999-12-30
DE69131796T2 true DE69131796T2 (de) 2000-06-29

Family

ID=27074101

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131796T Expired - Lifetime DE69131796T2 (de) 1990-08-10 1991-08-09 Analoge des ajca-ribosids

Country Status (10)

Country Link
EP (1) EP0495091B1 (de)
JP (3) JP3801620B2 (de)
AT (1) ATE186837T1 (de)
AU (1) AU656737B2 (de)
CA (1) CA2067151C (de)
DE (1) DE69131796T2 (de)
IE (1) IE912833A1 (de)
IL (1) IL99124A (de)
MX (1) MX9100611A (de)
WO (1) WO1992002214A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615556B2 (ja) * 1989-11-10 1994-03-02 旭化成工業株式会社 ４―カルバモイル―１―β―Ｄ―リボフラノシル―イミダゾリウム―５―オレイト無水結晶
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JP4172095B2 (ja) 1999-06-11 2008-10-29 日本精工株式会社 トロイダル型無段変速機
KR20070121026A (ko) 2005-03-28 2007-12-26 페리코르 테라퓨틱스, 인크. 환자에 있어서 부정적 영향을 방지하거나 감소시키기 위한방법, 조성물 및 제제
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
JP5591245B2 (ja) 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328261A (en) * 1964-02-24 1967-06-27 Kyowa Hakko Kogyo Kk Method for the fermentative production of 5-amino-4-imidazole carboxamide ribotide
AT350735B (de) * 1976-08-06 1979-06-11 Hoffmann La Roche Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
CA1317588C (en) * 1988-02-29 1993-05-11 Tohru Ueda Imidazole derivatives, process for production thereof, and use thereof
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose

Also Published As

Publication number Publication date
CA2067151A1 (en) 1992-02-11
EP0495091A4 (en) 1993-01-07
AU8624291A (en) 1992-03-02
JP2009102366A (ja) 2009-05-14
EP0495091A1 (de) 1992-07-22
WO1992002214A1 (en) 1992-02-20
JPH05502242A (ja) 1993-04-22
JP2005023086A (ja) 2005-01-27
IE912833A1 (en) 1992-02-12
AU656737B2 (en) 1995-02-16
MX9100611A (es) 1992-04-01
JP3801620B2 (ja) 2006-07-26
DE69131796D1 (de) 1999-12-30
IL99124A (en) 1998-02-22
CA2067151C (en) 2004-02-03
ATE186837T1 (de) 1999-12-15
IL99124A0 (en) 1992-07-15
EP0495091B1 (de) 1999-11-24

Similar Documents

Publication Publication Date Title
YU76100A (sh) Pirolo(2,3-d) pirimidin preparati i njihova primena
FI913236A0 (fi) 9-purinylfosfonsyraderivat.
SG46383A1 (en) 1, 3-Oxathiolane nucleoside analogues
EP0556334A4 (en) Polysubstituted benzimidazoles as antiviral agents
DE3852761T3 (de) Saponin-hilfsmittel.
DK713488D0 (da) Adenosinderivater
ES2074637T3 (es) Derivados de (fosfonometoxi)metoxi purina/pirimidina antiviricos.
DE69131796T2 (de) Analoge des ajca-ribosids
DE69132632T2 (de) Neue als Immunsuppressiva nützliche karbozyklische Adenosinanaloge
ATE372976T1 (de) Illudin analoge verwendet als antitumormittel
ES2021575B3 (es) Cuerpos moldeados de zeolita.
DK630589A (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
GB2340491A (en) Carbocyclic nucleoside hemisulfate and its use in treating viral infections
EP0540574A4 (de)
PT876146E (pt) Analogos de nucleosidos em terapia de combinacao de infeccoes por herpes simplex
DE3463657D1 (en) 2'-deoxy-3-phosphonylmethyl nucleosides and method for their preparation
ATE72122T1 (de) Antivirale mischungen.
GB9506644D0 (en) Preparation of nucleoside analogues
FI955257A0 (fi) 8-substituoidut-ksantiinit valikoivina adenosiinireseptoriaineina
NO921334L (no) Aica-ribosidanaloger
BR6700036U (pt) Disposicao introduzida em ferragem de fixacao
ES2034431T3 (es) Estante de banera.
ATE77386T1 (de) Therapeutische nucleoside.
HRP940041A2 (en) 1,3-oxathiolane nucleoside analogues
BR6600723U (pt) Esticador de couro

Legal Events

Date Code Title Description
8364 No opposition during term of opposition